We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

162 hedge funds and large institutions have $917M invested in Celldex Therapeutics in 2015 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 68 increasing their positions, 40 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 40

13% less funds holding

Funds holding: 186 → 162 (-24)

45% less call options, than puts

Call options by funds: $9.58M | Put options by funds: $17.5M

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

53% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 43

58% less capital invested

Capital invested by funds: $2.18B → $917M (-$1.27B)

Holders
162
Holders Change
-24
Holders Change %
-12.9%
% of All Funds
4.52%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
20
Increased
68
Reduced
40
Closed
43
Calls
$9.58M
Puts
$17.5M
Net Calls
-$7.92M
Net Calls Change
+$11.5M

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$36.3M
2
FCM
Frontier Capital Management
Massachusetts
+$18.9M
3
State Street
State Street
Massachusetts
+$11.3M
4
CWAM
Columbia Wanger Asset Management
Illinois
+$9.77M
5
First Trust Advisors
First Trust Advisors
Illinois
+$8.82M

Top Sellers

Rank Fund Capital Flow
1
TCM
TimesSquare Capital Management
New York
-$47.3M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$27M
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$21.2M
4
CCM
Consonance Capital Management
New York
-$19M
5
Citadel Advisors
Citadel Advisors
Florida
-$12.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$6.45M +$557K +1,968 +5%
CCI
27
Columbus Circle Investors
$6.25M -$1.43M -5,036 -11%
First Eagle Investment Management
28
First Eagle Investment Management
New York
$5.9M – – –
State of New Jersey Common Pension Fund D
29
State of New Jersey Common Pension Fund D
New Jersey
$5.01M +$1.23M +4,334 +16%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$4.89M -$21.2M -74,810 -71%
GC
31
Guggenheim Capital
Illinois
$4.37M +$1.12M +3,942 +17%
TCIM
32
TIAA CREF Investment Management
New York
$4M -$215K -758 -3%
FAM
33
Fred Alger Management
New York
$3.96M -$3.29M -11,626 -32%
AG
34
Artal Group
Luxembourg
$3.95M +$2.36M +8,333 +50%
TA
35
Teachers Advisors
New York
$3.68M +$19K +67 +0.3%
TCM
36
Tekla Capital Management
Massachusetts
$3.57M +$6.39M +22,560 New
BIM
37
BlackRock Investment Management
Delaware
$3.5M -$347K -1,225 -5%
Lord, Abbett & Co
38
Lord, Abbett & Co
New Jersey
$3.41M -$27M -95,276 -82%
JP Morgan Chase
39
JP Morgan Chase
New York
$3.32M +$608K +2,147 +11%
Charles Schwab
40
Charles Schwab
California
$3.28M +$115K +405 +2%
RPAM
41
Rhenman & Partners Asset Management
Sweden
$3.11M +$1.85M +6,534 +50%
Goldman Sachs
42
Goldman Sachs
New York
$2.68M -$2.38M -8,393 -33%
Zurich Cantonal Bank
43
Zurich Cantonal Bank
Switzerland
$2.57M +$4.59M +16,222 +54,073%
EAM
44
Eventide Asset Management
Massachusetts
$2.41M -$1.13M -3,994 -21%
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$2.32M – – –
Ameriprise
46
Ameriprise
Minnesota
$2.32M -$1.65M -5,837 -28%
FLAM
47
First Light Asset Management
Minnesota
$2.27M +$562K +1,986 +16%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$2.27M +$203K +717 +5%
SIP
49
Stoneridge Investment Partners
Pennsylvania
$2.22M +$615K +2,174 +18%
TI
50
Trexquant Investment
Connecticut
$2.21M +$3.32M +11,746 +520%
1
2
3 4 5

CLDX Hedge Fund Activity: Q3 2015 in Review

162 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2015, worth a combined $917M — down 58% from $2.18B a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of CLDX and 20 opened new positions — a net loss of 23 holders — while 40 trimmed existing stakes and 68 added.

The largest buyer was Redmile Group, adding an estimated $36.3M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $47.3M sold.

  • 162 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2015, down from 186 in Q2 2015.
  • Funds reported $917M of Celldex Therapeutics stock for Q3 2015, down 58% quarter-over-quarter.
  • 20 funds opened new Celldex Therapeutics positions in Q3 2015 and 43 closed out, a net change of -23 holders.
  • The largest Celldex Therapeutics buyer in Q3 2015 was Redmile Group, an estimated $36.3M added.
  • The largest Celldex Therapeutics seller in Q3 2015 was TimesSquare Capital Management, an estimated $47.3M sold.

Based on aggregated 13F filings for Q3 2015.